Treatment of Alzheimer's disease. New developments.

Cholinesterase inhibitors (ChEI) represent the drug of choice for Alzheimer's disease treatment. They produce significant improvement on cognitive as well as non-cognitive function for a period up to one year during the first three years period following clinical onset. The magnitude of cognitive improvements is similar for different ChEI; however, differences are seen with regard to incidence and severity of side effects, incidence of drop-outs, optimal ChE inhibition, pharmacokinetics properties and mode of administration.